These co-altered candidates include multiple putative drug targets elevated in HLRCC versus NS patients, such as arsenic trioxide targeting the NRF2-target gene thioredoxin reductase (TXNRD1), as well as additional metabolic targets including the cyclic heptapeptide CAP-232 (TLN-232) targeting the glycolytic enzyme complex resident protein pyruvate kinase M2 (Table 3). Here, TXNRD1 is linked to hereditary leiomyomatosis and renal cell cancer.